We found that, in agreement with previous studies [5, 24], mutations in multiple members of the PI3K pathway and KRAS were co-existed in several endometrial cancer cell lines, including concomitant mutations in the PI3K pathway. The gene discussed is KRAS; the disease is endometrial cancer.